Propanc Biopharma announces highlights of PRP

Propanc Biopharma (PPCB) announced highlights of PRP, its lead proenzyme therapy. The company said, “Conventional chemo hits walls of resistance, brutal toxicity, and minimal progress. PRP changes the game: 85% tumor growth inhibition demonstrated in preclinical pancreatic models; Forces malignant cells to differentiate-attacking cancer at its root; Reduces fibrosis and resistance markers in the tumor microenvironment; Sensitizes resistant tumors to standard chemo-higher efficacy, lower toxicity; Targets cancer stem cells to cut recurrence risk”